NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NeuroDerm Announces ND0612H Achieves Comparable Pharmacokinetics to DUODOPA® in Head-To-Head Pilot PK Comparison Trial
Company to Host Conference Call and Webcast Today at 8:30 a.m. ET .”> Read More
NeuroDerm Added to Russell Global Index
The company has been selected to join the Russell Global Index as part of the annual Russell Equity Index Reconstitution, effective as of June 27.”> Read More
NeuroDerm Presents Three Posters at the 20th International Congress of Parkinson’s Disease and Movement Disorders
Data Presented in the Posters Included Data on the Company’s New Apomorphine Product Candidate (ND0701) as well as Study Design of the First ND0612H Efficacy Trial (Trial 006) and Additional Data on the Effect of Continuous Subcutaneous Carbidopa Administration on Levodopa Plasma Levels ”> Read More